摘要
目的观察经过氧化酶体增殖因子活化受体γ(PPARγ)配体吡咯列酮预处理后急性坏死型胰腺炎(SAP)大鼠胰腺组织中核因子-(?)B(NF-(?)B)和细胞间粘附分子-1(ICAM-1)表达的变化.探讨PPARγ对大鼠SAP的干预治疗作用。方法54只健康雄性Sprague-Dawley大鼠,均分为假手术组(C组)、SAP组(A组)和吡格列酮预处理组(Ⅰ组)。采用逆行胰胆管内加压注射5%牛磺胆酸钠(0.1 ml/100 g)建立SAP模型。Ⅰ组大鼠在术前2 h腹腔内注射吡格列酮(2 mg/100 g)。分别于术后3、6、12 h 3个时段采用腹主动脉放血法将大鼠分批处死(每次每组6只),取血、腹水和胰腺组织。采用免疫组化二步法检测胰腺组织NF-(?)B和ICAM-1的表达.同时进行血清淀粉酶、腹水、胰腺大体病理、组织学评分和胰腺组织含水量测定。结果吡咯列酮预处理可明显减轻大鼠SAP严重程度,血清淀粉酶水平于6 h后降低;腹水量减少;胰腺组织大体和病理评分6 h后降低;组织含水量逐渐减少。吡咯列酮预处理后大鼠胰腺组织中ICAM-1表达减弱、NF-(?)B活性受到抑制(P值均<0.05)。结论吡咯列酮具有减轻SAP效应.可能是通过抑制NF-(?)B活性和ICAM-1表达起到抗炎作用.有望成为一种临床治疗SAP的有效新方法。
Objective To investigate the expression changes of nuclear factor-kappa B（NF-κB） and intercellular adhesion molecule-1 （ICAM-1） in rats with severe acute pancreatitis（SAP） and the effect of pretreatment of pioglitazone, a specific peroxisome proliferator-activated receptor γ（PPARγ） ligand, on the development of SAP. Methods Fifty-four SD rats were divided into sham operation group（C）, SAP group（A） and pioglitazone pretreatment group（Ⅰ）. The SAP was induced by retrograde infusion of 5% sodium taurocholate（0.1 ml/100 g） into the biliopancreatic duct. The rats in I group were intraperitoneally injected with pioglitazone（2 mg/100 g） two hours before operation. The rats were sacrificed at 3, 6 and 12 hrs, the blood, ascites and pancreatic tissues were collected（6 rats once for each group）. The expressions of NF-κB and ICAM-1 in pancreatic tissues were measured by immunochemistry, meanwhile the serum amylase, the amount of ascitic, pancreatic wet/dry ratio were measured. The pathological changes of pancreatic tissues were observed by immunochemistry staining with hematoxylin and eosin and the score of the tissues were evaluated. Results Pretreatment with pioglitazone could significantly attenuated the severity of SAP, including reduction of amylase and ascites, and the mass and pathological scores of the pancreatic tissue were decreased after 6 hrs of medication. The expression of ICAM-1 and NF-κB activity were inhibited. Conclusions Above findings demonstrate that pioglitazone can attenuate the severity of SAP by inhibition of ICAM-1 expression and NF-κB activation. The beneficial effects of pioglitazone might be due to its anti-inflammatory activities. The pioglitazone can be used as a new drug in treatment of SAP.
出处
《中华消化杂志》
CAS
CSCD
北大核心
2007年第7期461-463,共3页
Chinese Journal of Digestion
基金
江西省自然科学基金(0640069)
关键词
胰腺炎
核因子-ΚB
细胞间粘附分子-1
Pancreatitis
Nuclear factor kappa B
Intercellular adhesion molecule-1
